Lonza Group AG buy Quitte
Zusammenfassung
Diese Einschätzung wurde am 06.09.16 mit einem Endkurs von 172,48 € beendet. Aufwärts ging es für die BUY Einschätzung von Quitte mit einer Rendite von 16,04 %. Quitte hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Lonza Group AG | - | - | - | - |
| iShares Core DAX® | -2,20 % | -0,53 % | 12,49 % | 15,18 % |
| iShares Nasdaq 100 | -0,07 % | 1,84 % | 40,60 % | 43,70 % |
| iShares Nikkei 225® | -2,15 % | -1,11 % | 22,30 % | 3,14 % |
| iShares S&P 500 | -0,50 % | 1,48 % | 28,28 % | 41,94 % |
Kommentare von Quitte zu dieser Einschätzung
In der Diskussion Lonza Group AG diskutieren
Antikörpertherapie ist die Zukunft in die Krebstherapie
DUBLIN, June 13, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Combination Antibody Therapy for Cancer Treatment Overview " report to their offering.
Recombinant antibodies have been the shining jewels in the firmament of the pharma industry for almost the last two decades. They have returned billions of dollars in sales, and if their performance has not been the unalloyed triumph that was foreseen at their inception, they have, at least in some instances, produced impressive gains in patient response.
Today they are one of the most fundamental strategies for treating patients with hematological malignancies and solid tumors. This report explores the next level of therapy, combining antibodies with additional agents.
The report consists of eight chapters that address different aspects of the issue of combined antibody therapy - past, present, and future, topics include:
- A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
- Outlook for combination antibody therapeutics
- Targeted Antibody Therapeutics & Immuno-Antibody Therapeutics
- Development and Current Products
- Combination of Chemotherapy and Immuno-antibody therapeutics
- Combinations of immune-antibodies
- Immuno- antibody therapeutics in the marketplace
- Fusion Antibody Therapeutics
- Multitargeted and Polyfunctional Antibody Therapeutics
- Patent Expiration and the Rise of Biosimilars
- Biosimilar antibodies in the market
- Deals and the Marketplace
Interviews with Leading Experts:
- Interview with Esper Boel, SVP, head of discovery; Ivan Horak, CSO; and Mads Laustsen, CMO at Symphogen
- Interview with Eric S. Langer, Managing Partner, BioPlan Associates, Inc.
- Interview with Dr. Laurent Ducry, Group Leader Bioconjugates R&D, Lonza, Valais, Switzerland
- Interview with Dr. Cheng Liu, CEO, Eureka Therapeutics
- Interview with Steve King, President, Peregrine Pharma
Key Topics Covered:
Chapter 1 - Introduction, Scope and Objectives
Chapter 2 - Targeted Antibody Therapeutics
Chapter 3 - Immuno-Antibody Therapeutics
Chapter 4 - Fusion Antibody Therapeutics
Chapter 5 - Multitargeted and Polyfunctional Antibody Therapeutics
Chapter 6 - Patent Expiration and the Rise of Biosimilars
Chapter 7 - Deals and the Marketplace
Chapter 8 - Strategic Issues
Chapter 9 - Interviews with Experts in the Field
Chapter 10 - Questionnaire put to Industry Representatives Concerning Developments in Antibody Technology
Companies Mentioned
- BioPlan Associates, Inc.
- Eureka Therapeutics
- Lonza Group
- Peregrine Pharmaceuticals
- Symphogen
For more information visit http://www.researchandmarkets.com/research/wfxtcj/combination